Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato Sells 3,080 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Vicki L. Sato sold 3,080 shares of the firm's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now owns 107,976 shares of the company's stock, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Denali Therapeutics Stock Up 2.0 %

Shares of Denali Therapeutics stock traded up $0.42 on Friday, reaching $21.26. The company's stock had a trading volume of 642,314 shares, compared to its average volume of 670,407. Denali Therapeutics Inc. has a 52-week low of $14.56 and a 52-week high of $33.33. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.35. The stock has a 50-day moving average price of $24.62 and a 200-day moving average price of $24.85.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business posted ($0.72) EPS. Sell-side analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DNLI has been the subject of a number of recent research reports. Jefferies Financial Group raised their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. William Blair initiated coverage on shares of Denali Therapeutics in a report on Friday. They set an "outperform" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price target on shares of Denali Therapeutics in a report on Thursday, November 7th. Stifel Nicolaus upgraded Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price objective for the company in a research note on Monday, December 16th. Finally, Cantor Fitzgerald cut Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $40.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC lifted its position in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after acquiring an additional 654 shares in the last quarter. Quest Partners LLC acquired a new stake in Denali Therapeutics during the third quarter worth about $73,000. Assetmark Inc. boosted its holdings in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after purchasing an additional 580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after buying an additional 920 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Denali Therapeutics in the 2nd quarter valued at approximately $194,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.